Colorectal CancerNCT04144738
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"
An observational study of Colorectal Cancer, run by Exact Sciences Corporation at 195 sites in United States.
Trial summary
The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test. Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Colorectal Cancer
- What is being tested?
- mt-sDNA 2.0 screening test, FIT test and Colonoscopy
- Type of treatment
- Surgery or procedure
- How many people
- 26,758 participants
- Where
- 195 sitesUnited States
- Study dates
- 15 Nov 2019to 30 Mar 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Subjects 40 years of age and older who are eligible for CRC screening and scheduled for a screening colonoscopy. 24,000 subjects are targeted to enroll.
Who may be able to join
- Subjects must meet the following criteria to be eligible for the study:
- Subject is ≥ 40 years of age at the time of enrollment.
- Subject presents for a screening colonoscopy per standard of care.
- Subject has no symptoms or signs that require immediate, or near term, referral for diagnostic or therapeutic colonoscopy.
- Subject is able and willing to sign informed consent
Who cannot join
- Subject has a history of CRC or advanced precancerous lesions.
- Subject has a diagnosis or medical / family history of any of the following conditions, including:
- Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome),
- Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome"),
- Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis, or Familial Hyperplastic Polyposis.
- Subject has a diagnosis or personal history of inflammatory bowel disease (IBD) including chronic ulcerative colitis and/or Crohn's disease.
Show all 11Show fewer
- Subject has a diagnosis of Cronkhite-Canada Syndrome.
- Subject has had a positive Cologuard within the previous 2 years, or fecal occult blood test or FIT within the previous 6 months.
- Subject has undergone a colonoscopy within the previous 9 years with the exception of a failed colonoscopy due to poor bowel preparation. Failed colonoscopy must have been within the past year and without therapeutic intervention.
- Subject has had overt rectal bleeding within the previous 30 days.
- Subject has any condition that in the opinion of the Investigator should preclude participation in the study.
Trial locations and contacts
195 sites in 1 country.
195 sites in 1 country
United States195 sites
Cornerstone Research Institute
Altamonte Springs, Florida, 32701
PMG Research
Ames, Iowa, 50010
University of Michigan
Ann Arbor, Michigan, 48109
Gastro Health Research
Annapolis, Maryland, 21401
Digestive Health Partners, PA
Asheville, North Carolina, 28801
Summit Clinical Research, LLC
Athens, Georgia, 30607
Augusta University
Augusta, Georgia, 30912
ARC Clinical Research at Four Points
Austin, Texas, 78726
Elligo Health Research Inc.
Austin, Texas, 78738
ARC Clinical Research at William Cannon
Austin, Texas, 78745
Avant Research Associates
Austin, Texas, 78748
Margaret Mary Health
Batesville, Indiana, 47006
Great Lakes Medical Research, LLC
Beachwood, Ohio, 44122
United Health Services Hospitals, Inc.
Binghamton, New York, 13903
Parkway Medical Center
Birmingham, Alabama, 35215
Summit Internal Medicine, PC
Birmingham, Alabama, 35243
University of Alabama at Birmingham
Birmingham, Alabama, 35294
Massachusetts General Hospital
Boston, Massachusetts, 02114
Beth Israel Deaconess Medical Center - Harvard
Boston, Massachusetts, 02215
Progressive Clinical Research, LLC
Bountiful, Utah, 84010
Gastroenterology Associates of Fairfield County
Bridgeport, Connecticut, 06606
Bridgeport Hospital
Bridgeport, Connecticut, 06610
Connecticut Clinical Research Institute
Bristol, Connecticut, 06010
VA NY Harbor HCS- Brooklyn Campus
Brooklyn, New York, 11209
Fomat Medical Research
Camarillo, California, 93012
IQVIA RDS, Inc.
Cambridge, Massachusetts, 02139
Alliance Research Institute
Canoga Park, California, 91304
Christie Clinic, LLC
Champaign, Illinois, 61882
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
Ralph H. Johnson VAMC
Charleston, South Carolina, 29401
Pharmacorp Clinical Trials, Inc.
Charleston, South Carolina, 29412
Atrium Health Department of Family Medicine Research
Charlotte, North Carolina, 28207
Javara
Charlotte, North Carolina, 28210
WR-ClinSearch, LLC
Chattanooga, Tennessee, 37421
Digestive Health Specialists, PC
Chelmsford, Massachusetts, 01824
Clinical Research Professionals
Chesterfield, Missouri, 63005
Chevy Chase Clinical Research
Chevy Chase, Maryland, 20815
Rush University Medical Center
Chicago, Illinois, 60612
GW Research Inc
Chula Vista, California, 91910
Gastro Health Research
Cincinnati, Ohio, 45219
Hightop Medical Research Clinic
Cincinnati, Ohio, 45224
University Hospitals Cleveland Medical Center
Cleveland, Ohio, 44106
Cullman Clinical Trials
Cullman, Alabama, 35055
Mercy Family Clinic
Dallas, Texas, 75211
Dharma PA D/B/A Southwest Family Medicine Associates
Dallas, Texas, 75235
Dayton Clinical Resesarch
Dayton, Ohio, 45409
META Medical Research Institute, LLC
Dayton, Ohio, 45432
Atlanta Center for Gastroenterology, P.C.
Decatur, Georgia, 30033
Digestive Health Specialists of the Southeast
Dothan, Alabama, 36301
GI Partners of IL / Avicenna
Downers Grove, Illinois, 60515
St. Elizabeth Healthcare
Edgewood, Kentucky, 41017
AGA Clinical Research Associates, LLC
Egg Harbor, New Jersey, 08234
Texas Tech University Health Sciences Center El Paso
El Paso, Texas, 79905
Centennial Medical Group
Elkridge, Maryland, 21075
Horizon Research Group of Opelousas, LLC
Eunice, Louisiana, 70535
Deaconess Clinic, Inc.
Evansville, Indiana, 47713
NECCR PrimaCare Research, LLC
Fall River, Massachusetts, 02721
Lillestol Research, LLC
Fargo, North Dakota, 58104
Plains Clinical Research Center, LLC
Fargo, North Dakota, 58104
Coastal Research Institute, LLC
Fayetteville, North Carolina, 28304
Sing Chan, MD
Flushing, New York, 11354
G & L Research
Foley, Alabama, 36535
Vanguard Clinical Research
Fort Myers, Florida, 33907
Methodist Physicians Clinic / CCT Research
Fremont, Nebraska, 68025
SIMED Health Research
Gainesville, Florida, 32607
Digestive Health Center of the Four States, LLC
Galena, Kansas, 66739
Paragon Rx Clinical, Inc.
Garden Grove, California, 92840
Gastro One
Germantown, Tennessee, 38138
New West Physicians
Golden, Colorado, 80401
Medication Management LLC
Greensboro, North Carolina, 27405
Great Lakes Medical Research, LLC
Harrisburg, Pennsylvania, 17110
Peters Medical Research
High Point, North Carolina, 27262
Edward Hines Jr. VA Hospital
Hines, Illinois, 60141
Houma Digestive Health Specialists-CroNOLA
Houma, Louisiana, 70360
Houston Digestive Disease
Houston, Texas, 77030
UT MD Anderson Cancer Center
Houston, Texas, 77030
Biopharma Informatic, LLC
Houston, Texas, 77084
Fairway Medical Clinic
Houston, Texas, 77087
Digestive System Healthcare
Houston, Texas, 77505
University Physicians and Surgeons, Inc. DBA Marshall Health
Huntington, West Virginia, 25701
Medical Affiliated Research Center
Huntsville, Alabama, 35801
Hutchinson Clinic
Hutchinson, Kansas, 67502
Grand Teton Research Group
Idaho Falls, Idaho, 83404
Richard L. Roudebush VA Medical Center
Indianapolis, Indiana, 46202
University of Iowa
Iowa City, Iowa, 52242
United Medical Doctors
Irvine, California, 92618
Southern Therapy and Advanced Research LLC (STAR)
Jackson, Mississippi, 39216
The Jackson Clinic, PA
Jackson, Tennessee, 38301
Clinical Research Solutions, LLC - TN
Jackson, Tennessee, 38305
The Jackson Clinic, PA
Jackson, Tennessee, 38305
Westside Center of Clinical Research
Jacksonville, Florida, 32205
Shands Jacksonville Medical Center, Inc - University of Florida Health
Jacksonville, Florida, 32206
Richard M. Kastelic, M.D., and Associates, P.C.
Johnstown, Pennsylvania, 15905
Health Awareness, Inc.
Jupiter, Florida, 33458
Tri-Cities
Kingsport, Tennessee, 37663
Combined Gastro Research, LLC
Lafayette, Louisiana, 70503
Prime Care Clinical Research Center
Laguna Hills, California, 92656
Clinical Trials of SWLA, LLC
Lake Charles, Louisiana, 70601
Wr-Msra, Llc
Lake City, Florida, 32055
FMC Science, LLC
Lampasas, Texas, 76550
Gastro Care Institute
Lancaster, California, 93534
Regional GI
Lancaster, Pennsylvania, 17601
University of Nevada, Las Vegas
Las Vegas, Nevada, 89102
Clinical Research of South Nevada
Las Vegas, Nevada, 89121
Tanner Clinic
Layton, Utah, 84041
Pioneer Clinical Research
Lighthouse PT, Florida, 33064
Lynn Institute of the Ozarks
Little Rock, Arkansas, 72204
Applied Research Center of Arkansas
Little Rock, Arkansas, 72212
Blue Ridge Medical Research
Lynchburg, Virginia, 24502
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, 53215
Rio Grande Gastroenterology
McAllen, Texas, 78503
Wellness Clinical Research
McKinney, Texas, 75071
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio, 44060
Clinical Trials Management, LLC
Metairie, Louisiana, 70006
New Orleans Research Institute
Metairie, Louisiana, 70006
Suncoast Research Group, LLC
Miami, Florida, 33135
Next Phase Research Alliance
Miami, Florida, 33144
Research Associates of South Florida, LLC
Miami, Florida, 33156
Gastro Health Research
Miami, Florida, 33176
Paramount Medical Research and Consulting, LLC
Middleburg Heights, Ohio, 44130
Ascension Wisconsin
Milwaukee, Wisconsin, 53211
Wisconsin Center for Advanced Research
Milwaukee, Wisconsin, 53215
Facey Medical Foundation
Mission Hills, California, 91345
East View Medical Research, LLC
Mobile, Alabama, 36608
Delta Research Partners
Monroe, Louisiana, 71201
Infinite Clinical Trials
Morrow, Georgia, 30260
Clinical Trials of America, LLC
Mount Airy, North Carolina, 27030
Gastroenterology Group of Naples
Naples, Florida, 34102
Coastal Carolina Health Care, P.A.
New Bern, North Carolina, 28562
Yale University
New Haven, Connecticut, 06519
Mid Hudson Medical Research, PLLC
New Windsor, New York, 12553
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
Deaconess Clinic, Inc.
Newburgh, Indiana, 47630
Alliance for Multispecialty Research, LLC
Norman, Oklahoma, 73069
Arkansas Gastroenterology, P.A.
North Little Rock, Arkansas, 72117
DiGiovanna Institute for Medical Education & Research
North Massapequa, New York, 11758
Southwest Gastroenterology
Oak Lawn, Illinois, 60453
Sarkis Clinical Trials
Ocala, Florida, 34471
Advanced Research Institute
Ogden, Utah, 84405
SSM Health Medical Group/Hightower Clinical
Oklahoma City, Oklahoma, 73102
CHI Nebraska
Omaha, Nebraska, 68124
Knowledge Research Center
Orange, California, 92868
Desert Oasis Healthcare Medical Group
Palm Springs, California, 92262
Imic, Inc.
Palmetto Bay, Florida, 33157
Palo Alto Veterans Institute for Research
Palo Alto, California, 34304
Summit Clinical Research
Petersburg, Virginia, 23805
ARC Clinical Research at Kelly Lane
Pflugerville, Texas, 78660
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107
Mayo Clinic - AZ
Phoenix, Arizona, 85054
Family Medical Specialists of Florida, PLC
Plant City, Florida, 33563
Care Access Research, Pottsville
Pottsville, Pennsylvania, 17901
Rapid City Medical Center, LLP
Rapid City, South Dakota, 57701
Epic Medical Research, LLC
Red Oak, Texas, 75154
Digestive Health Associates
Reno, Nevada, 89511
Central Virginia VA Healthcare System
Richmond, Virginia, 23249
Advanced Clinical Research
Riverton, Utah, 84065
Granger Medical Clinic
Riverton, Utah, 84096
Mayo Clinic
Rochester, Minnesota, 55905
Clinical Associates in Research Therapeutics of America
San Antonio, Texas, 78212
Gastroenterology Research of San Antonio
San Antonio, Texas, 78229
SDG Clinical Research
San Diego, California, 92103
San Jose Gastroenterology
San Jose, California, 95116
Advanced Research Institute
Sandy City, Utah, 84092
Paragon Rx Clinical, Inc. - Santa Ana
Santa Ana, California, 92703
Sansum Clinic
Santa Barbara, California, 93105
Benaroya Research Institute at Virginia Mason
Seattle, Washington, 98101
Unison Clinical Trials
Sherman Oaks, California, 91403
Louisiana Research Center; Gastrointestinal Associates
Shreveport, Louisiana, 71105
The South Bend Clinic
South Bend, Indiana, 46617
Spokane Gastroenterology
Spokane, Washington, 99202
Sundance Clinical Research, LLC
St Louis, Missouri, 63141
Alternative Solutions, LLC
St. Petersburg, Florida, 33711
Virginia Gastroenterology Institute
Suffolk, Virginia, 23434
Precision Clinical Research, LLC
Sunrise, Florida, 33351
Clinical Trials of Tampa
Tampa, Florida, 33614
Millennium Clinical Trials
Thousand Oaks, California, 91360
Texas Gastro Consultants
Tomball, Texas, 77375
Oakland Medical Research
Troy, Michigan, 48085
Clinical Research Institute of Michigan, LLC
Troy, Michigan, 48098
Del Sol Research Management, LLC
Tucson, Arizona, 85712
Southern Arizona VA Health Care System (SAVAHCS)
Tucson, Arizona, 85723
Options Health Research, LLC
Tulsa, Oklahoma, 74104
GI Associates of West Alabama, P.C
Tuscaloosa, Alabama, 35406
Great Lakes Medical Research, LLC
Union City, Tennessee, 38261
Dream Team Clinical Research
Upland, California, 91786
Wenatchee Valley Hospital
Wenatchee, Washington, 98801
Invocare Medical Research & Healthcare Center
West Columbia, South Carolina, 29169
The Iowa Clinic, P.C.
West Des Moines, Iowa, 50266
Allied Health Clinical Research Organization, LLC
West Long Branch, New Jersey, 07728
Clinical Trials of America, LLC
West Monroe, Louisiana, 71291
Northshore Gastroenterology Research, LLC
Westlake, Ohio, 44145
Ascension Via Christi Hospitals Wichita, Inc
Wichita, Kansas, 67214
Trial Management Associates, LLC
Wilmington, North Carolina, 28403
Comprehensive Internal Medicine, Inc
Wooster, Ohio, 44691
University of Massachusetts - Worcester
Worcester, Massachusetts, 01655
About this study
The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test.
Read the detailed description
Subjects 40 years of age and older scheduled for a screening colonoscopy will be enrolled. Subject will complete the mt-sDNA 2.0 test and the commercially available FIT, followed by completion of a screening colonoscopy. The results of the mt-sDNA screening test and FIT will not be provided to investigators for clinical management of the study subject. Personnel performing the colonoscopy and producing the resulting report and personnel performing histopathologial review of reports or tissue (if applicable) will remain blinded to the results of the mt-sDNA 2.0 screening test results.
- Conditions
- Colorectal Cancer
- Being tested
- mt-sDNA 2.0 screening test, FIT test, Colonoscopy
- Keywords
- Sample Collection, Stool DNA, Colonoscopy
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
mt-sDNA 2.0 screening testDiagnostic test
Stool samples will be collected by the subject for the mt-sDNA screening test.
FIT testDiagnostic test
Stool samples will be collected by the subject for the FIT test.
ColonoscopyProcedure or surgery
Subjects will undergo a screening colonoscopy.
| Study group | Role | What they receive |
|---|---|---|
| Individuals eligible for CRC Screening | Individuals who are 40 years of age and older, eligible for CRC screening, and scheduled for a screening colonoscopy. Receives: Diagnostic Test: mt-sDNA 2.0 screening test; Diagnostic Test: FIT test; Procedure: Colonoscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sensitivity for CRC with the mt-sDNA 2.0 test
Measured: Through study completion, an average of 180 days
Specificity with the mt-sDNA 2.0 test
Measured: Through study completion, an average of 180 days
Secondary outcomes (4)
Sensitivity for advanced precancerous lesions
Measured: Through study completion, an average of 180 days
Sensitivity for CRC compared to a commercially available fecal immunochemical test (FIT)
Measured: Through study completion, an average of 180 days
Sensitivity for advanced precancerous lesions compared to commercially available fecal immunochemical test (FIT).
Measured: Through study completion, an average of 180 days
Specificity for no colorectal neoplastic findings
Measured: Through study completion, an average of 180 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2019
- Study start15 Nov 2019
- Primary completion30 Mar 2023
- Study completion30 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 26,758 participants (actual)
Sponsor and investigators
- Lead sponsor
- Exact Sciences Corporation
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Thomas Imperiale, MD, Principal investigator, Indiana University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04144738
- Sponsor's protocol ID
- 2019-01
- Status last verified
- Aug 2023
- First submitted
- 28 Oct 2019
- Last updated
- 1 Sep 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie the results reported in publications of the study may be shared after de-identification. This may include text, tables, figures, and appendices. The study protocol, statistical analysis plan, and informed consent form may also be shared. Data may be shared with researchers who provide a methodologically sound proposal to achieve the aims outlined in the approved proposal.
Publications
Imperiale TF, Gagrat ZD, Krockenberger M, Porter K, Ziegler E, Leduc CM, Matter MB, Olson MC, Limburg PJ. Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer. Gastro Hep Adv. 2024 May 17;3(6):740-748. doi: 10.1016/j.gastha.2024.05.002. eCollection 2024.
PubMed 39280922Imperiale TF, Porter K, Zella J, Gagrat ZD, Olson MC, Statz S, Garces J, Lavin PT, Aguilar H, Brinberg D, Berkelhammer C, Kisiel JB, Limburg PJ; BLUE-C Study Investigators. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):984-993. doi: 10.1056/NEJMoa2310336.
PubMed 38477986Gagrat ZD, Krockenberger M, Bhattacharya A, Gagrat BZ, Leduc CM, Matter MB, Fourrier KD, Mahoney DW, Edwards V DK, Lidgard GP, Limburg PJ, Johnson SC, Domanico MJ, Kisiel JB. Next-generation Multi-target Stool DNA Panel Accurately Detects Colorectal Cancer and Advanced Precancerous Lesions. Cancer Prev Res (Phila). 2024 Mar 4;17(3):119-126. doi: 10.1158/1940-6207.CAPR-23-0285.
PubMed 38224564
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening "BLUE-C"
- ClinicalTrials.gov ID
- NCT04144738
- Acronym / sponsor ID
- 2019-01
- Conditions
- Colorectal Cancer
- Keywords
- Sample Collection, Stool DNA, Colonoscopy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 26,758 participants (actual)
- Lead sponsor
- Exact Sciences CorporationIndustry (pharma, biotech, devices)
- Study start
- 15 Nov 2019 (actual)
- Primary completion
- 30 Mar 2023 (actual)
- Study completion
- 30 Mar 2023 (actual)
- First posted
- 30 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to assess the sensitivity for colorectal cancer (CRC) and specificity of the mt-sDNA 2.0 test.
Detailed description
Subjects 40 years of age and older scheduled for a screening colonoscopy will be enrolled. Subject will complete the mt-sDNA 2.0 test and the commercially available FIT, followed by completion of a screening colonoscopy. The results of the mt-sDNA screening test and FIT will not be provided to investigators for clinical management of the study subject. Personnel performing the colonoscopy and producing the resulting report and personnel performing histopathologial review of reports or tissue (if applicable) will remain blinded to the results of the mt-sDNA 2.0 screening test results.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Individuals eligible for CRC Screening | – | Diagnostic Test: mt-sDNA 2.0 screening test, Diagnostic Test: FIT test, Procedure: ColonoscopyIndividuals who are 40 years of age and older, eligible for CRC screening, and scheduled for a screening colonoscopy. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Subjects 40 years of age and older who are eligible for CRC screening and scheduled for a screening colonoscopy. 24,000 subjects are targeted to enroll.
Key inclusion criteria (5 listed)
- Subject is ≥ 40 years of age at the time of enrollment.
- Subject presents for a screening colonoscopy per standard of care.
- Subject has no symptoms or signs that require immediate, or near term, referral for diagnostic or therapeutic colonoscopy.
- Subject is able and willing to sign informed consent
Key exclusion criteria (11 listed)
- Subject has a history of CRC or advanced precancerous lesions.
- Subject has a diagnosis or medical / family history of any of the following conditions, including:
- Subject has a diagnosis or personal history of inflammatory bowel disease (IBD) including chronic ulcerative colitis and/or Crohn's disease.
- Subject has a diagnosis of Cronkhite-Canada Syndrome.
- Subject has had a positive Cologuard within the previous 2 years, or fecal occult blood test or FIT within the previous 6 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| mt-sDNA 2.0 screening testStool samples will be collected by the subject for the mt-sDNA screening test. | Diagnostic test | Individuals eligible for CRC Screening |
| FIT testStool samples will be collected by the subject for the FIT test. | Diagnostic test | Individuals eligible for CRC Screening |
| ColonoscopySubjects will undergo a screening colonoscopy. | Procedure or surgery | Individuals eligible for CRC Screening |
Primary outcome
Sensitivity for CRC with the mt-sDNA 2.0 test
Time frame: Through study completion, an average of 180 days
Specificity with the mt-sDNA 2.0 test
Time frame: Through study completion, an average of 180 days
4 secondary outcomes
Sensitivity for advanced precancerous lesions
Time frame: Through study completion, an average of 180 days
Sensitivity for CRC compared to a commercially available fecal immunochemical test (FIT)
Time frame: Through study completion, an average of 180 days
Sensitivity for advanced precancerous lesions compared to commercially available fecal immunochemical test (FIT).
Time frame: Through study completion, an average of 180 days
Specificity for no colorectal neoplastic findings
Time frame: Through study completion, an average of 180 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2023.
- Derived from this study: PubMed 39280922Imperiale TF, Gagrat ZD, Krockenberger M, Porter K, Ziegler E, Leduc CM, Matter MB, Olson MC, Limburg PJ. Algorithm Development and Early Performance Evaluation of a Next-Generation Multitarget Stool DNA Screening Test for Colorectal Cancer. Gastro Hep Adv. 2024 May 17;3(6):740-748. doi: 10.1016/j.gastha.2024.05.002. eCollection 2024.
- Derived from this study: PubMed 38477986Imperiale TF, Porter K, Zella J, Gagrat ZD, Olson MC, Statz S, Garces J, Lavin PT, Aguilar H, Brinberg D, Berkelhammer C, Kisiel JB, Limburg PJ; BLUE-C Study Investigators. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. N Engl J Med. 2024 Mar 14;390(11):984-993. doi: 10.1056/NEJMoa2310336.
- Derived from this study: PubMed 38224564Gagrat ZD, Krockenberger M, Bhattacharya A, Gagrat BZ, Leduc CM, Matter MB, Fourrier KD, Mahoney DW, Edwards V DK, Lidgard GP, Limburg PJ, Johnson SC, Domanico MJ, Kisiel JB. Next-generation Multi-target Stool DNA Panel Accurately Detects Colorectal Cancer and Advanced Precancerous Lesions. Cancer Prev Res (Phila). 2024 Mar 4;17(3):119-126. doi: 10.1158/1940-6207.CAPR-23-0285.
- Individual participant dataSharing planned: Yes. Individual participant data that underlie the results reported in publications of the study may be shared after de-identification. This may include text, tables, figures, and appendices. The study protocol, statistical analysis plan, and informed consent form may also be shared. Data may be shared with researchers who provide a methodologically sound proposal to achieve the aims outlined in the approved proposal.
Related trials for Colorectal Cancer
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 1
A Study of MGC030 in Participants With Advanced Solid Tumors
Urothelial Cancer, GastroEsophageal Cancer
Active, not recruitingObservational study
The IMPACT Study - Identification of Men With a Genetic Predisposition to ProstAte Cancer
Prostate Cancer, BRCA Mutation
RecruitingObservational study
ABCSG R07 Rectal Cancer Registry
Rectal Cancer, Adenocarcinoma of Rectum
Recruiting
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
Cancer, Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thomas Imperiale, MD principal investigator
Indiana University
195 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer, run by Exact Sciences Corporation at 195 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 195 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sensitivity for CRC with the mt-sDNA 2.0 test (time frame: Through study completion, an average of 180 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04144738, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2023.